(Batesville, IN) – Batesville Middle School will host its annual Veterans Day Program on Tuesday, November 11 at 9 a.m. in ...

Bristol Myers Squibb is shedding two clinical programs, one from its 2023 Mirati buyout and another from a partnership with U ...

This year, BMS partnered to develop a PD-L1 and VEGF bispecific antibody and has acquired the rights to a new radiopharmaceutical asset.

The consequences of President Trump's actions on drug pricing continue to play out, with Bristol Myers Squibb insisting it will charge the same in the UK for new schizophrenia drug Cobenfy as in the ...

During BMS’ earnings call Thursday, CEO Chris Boerner, Ph.D., described Cobenfy as “delivering steady growth.” But the first-in-class drug still has a long way to go to fulfill its promise as a ...

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical supply and collaboration agreement with ...

CD19 chimeric antigen receptor T-cell therapy improved lung function and skin thickness in patients with severe refractory ...

CytomX Therapeutics Inc. (($CTMX)) has held its Q3 earnings call. Read on for the main highlights of the call. CytomX Therapeutics Inc. recently ...

Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies – for $1.5 billion in cash. Cambridge, Massachusetts-based Orbital is ...

The event brought together the BHS chorus, BHS drama, BHS art, and the BMS chorus at the high school’s Performing Arts Center ...

Nonprofit hospitals and health clinics are alarmed about a change that's coming to federal drug purchasing discounts next ...

Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine ...